Anti-tumor mAbs are the most widely used and characterized cancer immunotherapy agents. 23 Despite having a significant impact on some malignancies, most cancer patients respond poorly 24 or develop resistance to this therapy. A known mechanism of action of these therapeutic mAbs is 25 antibody-dependent cell-mediated cytotoxicity (ADCC), which is a primarily effector function of 26 NK cells. CD16A on human NK cells has an exclusive role in binding to tumor-bound IgG 27
Introduction 45
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that target 46 stressed, infected, and neoplastic cells (1). In contrast to the diverse array of receptors involved 47 in natural cytotoxicity, human NK cells mediate ADCC exclusively through the IgG Fc receptor was performed using TeSR-E8 medium and a STEMdiff Hematopoietic Kit (StemCell 126 Technologies), which did not require the use of mouse embryonic fibroblast feeder cells, TrypLE 127 adaption, spin embryoid body formation, or CD34 + cell enrichment. iPSC cells during passage 128
were dissociated with Gentle Cell Dissociation Reagent (StemCell Technologies), and iPSC 129 aggregates ≥ 50 µm in diameter were counted with a hemocytometer and diluted to 20 -40 130 aggregates/ml with TeSR-E8 medium. Each well of a 12-well plate was pre-coated with Matrigel 131
Matrix (Corning Inc., Tewksbury, MA) and seeded with 40 -80 aggregates in 2 ml of TeSR-E8 132 medium. Cell aggregates were cultured for 24 hours before differentiation with the STEMdiff 133
Hematopoietic Kit, as per the manufacturer's instructions. At day 12 of hematopoietic progenitor 134 cell differentiation, the percentage of hematopoietic progenitor cells was determined using flow 135 cytometric analysis with anti-CD34, anti-CD45, and anti-CD43 mAbs. NK cell differentiation 136 was performed as previously described (32) . The iPSC-derived NK cells (referred to here as iNK 137 cells) were expanded for examination using γ-irradiated K562-mbIL21-41BBL feeder cells (1:2 138 ratio) in cell expansion medium [60% DMEM, 30% Ham's F12, 10% human AB serum (Valley 139 Biomedical, Winchester, VA), 20µM 2-mercaptoethanol, 50 µM ethanolamine, 20 µg/ml 140 ascorbic Acid, 5 ng/ml sodium selenite, 10 mM HEPES, and 100-250 IU/ml IL-2 (R&D 141
Systems)], as described previously (14, (29) (30) (31) .. 142 143
Cell staining, flow cytometry and ELISA. 144 For cell staining, nonspecific antibody binding sites were blocked and cells were stained with the 145 indicated antibodies and examined by flow cytometry, as previously described (11, 14, 33 FACSCelesta instrument (BD Biosciences). Data was analyzed using FACSDIVA v8 (BD 169 Biosciences) and FlowJo v10 (Ashland, OR). 170 171
Cell-cell conjugation assay and ADCC. 172
The pBMN-IRES-EGFP vector used to express CD64/16A in NK92 cells also expresses eGFP. 173
These cells were incubated for 2 hours at 37 o C in MEM-α basal media (Thermo Fisher  174 Scientific, Waltham, MA) supplemented with IL-2 (200 IU/ml), HEPES (10mM), and 2-175 mercaptoethanol (0.1 mM). SKOV-3 cells were labeled with CellTrace Violet (Molecular 176
Probes, Eugene, OR) per the manufacturer's instructions, incubated with 5μg/ml trastuzumab for 177 30 minutes and washed with the MEM-α basal media. NK92 cells and SKOV-3 cells were then 178 resuspended in the supplemented MEM-α basal media at 1x10 6 and 2x10 6 /ml, respectively. For a 179 1:2 Effector:Target (E:T) ratio, 100μl of each cell type was mixed together, centrifuged for 1 180 minute at 20×g and incubated at 37 o C for the indicated time points. After each time point, the 181 cells were gently vortexed for 3 seconds and immediately fixed with 4 o C 1% paraformaldehyde 182 in dPBS. Samples were immediately analyzed by flow cytometry. 
RESULTS

212
Expression and function of CD64/16A in NK92 cells. 213 We engineered a recombinant FcγR that consists of the extracellular region of human CD64 and 214 the transmembrane and cytoplasmic regions of human CD16A, referred to as CD64/16A ( Fig.  215  1A) . The recombinant receptor was stably expressed in the human NK cell line NK92. These 216 cells lack endogenous FcγRs but transduced cells expressing exogenous CD16A can mediate 217 ADCC (14, 20, 27) . As shown is Figure 1B , an anti-CD64 mAb stained NK92 cells expressing 218 CD64/16A cells, but not parent NK92 cells or NK92 cells expressing CD16A. An anti-CD16 219 mAb stained NK92 cells expressing CD16A, but not NK92 cells expressing CD64/16A or parent 220 NK92 cells (Fig. 1B) . CD16A undergoes ectodomain shedding by ADAM17 upon NK cell 221 activation resulting in its rapid downregulation in expression (10-13, 33). CD16A and its isoform 222 CD16B on neutrophils is cleaved by ADAM17 (10), and this occurs at an extracellular region 223
proximal to the cell membrane (13, 14) . The ADAM17 cleavage region of CD16A is not present 224 in CD64 or CD64/16A (Fig. 1A) . We found that CD16A underwent a >50% decrease in 225 expression upon NK92 stimulation by ADCC, whereas CD64/16A demonstrated little to no 226 downregulation (Fig. 1C) .
228
To evaluate the function of CD64/16A, we examined its ability to initiate E:T conjugation, 229
induce ADCC, and stimulate IFN-g production upon NK cell engagement of antibody-bound 230 tumor cells. Prior to the release of its granule contents, an NK cell must form a stable conjugate 231 with a target cell. Using a two-color flow cytometric approach, we examined the conjugation of 232 NK92-CD64/16A cells and SKOV-3 cells, an ovarian cancer cell line that expresses HER2. This 233 assay was performed in the absence and presence of the anti-HER2 therapeutic mAb 234 trastuzumab. The bicistronic vector containing CD64/16A also expressed eGFP and its 235 fluorescence was used to identify the NK92 cells. SKOV-3 cells were labeled with the 236 fluorescent dye CellTrace Violet. E:T conjugation resulted in two-color events that were 237 enumerated by flow cytometry. The incubation of NK92-CD64/16A cells with SKOV-3 cells 238 resulted in a very low level of conjugation after initial exposure that increased after 60 minutes 239 of exposure ( Fig. 2A) . However, in the presence of trastuzumab, NK92-CD64/16A cell and 240 SKOV-3 conjugation was appreciably enhanced ( Fig. 2A) . This increase in conjugation 241 corresponded with higher levels of target cell killing. As shown in Figure 2B , SKOV-3 cell 242 cytotoxicity by NK92-CD64/16A cells varied depending on the trastuzumab concentration and 243 E:T ratio. To confirm the role of CD64/16A in the induction of target cell killing, we performed 244 the ADCC assay in the presence and absence of the anti-CD64 mAb 10.1 (Fig. 2C) , which 245
blocks IgG binding (34). Cytokine production is also induced during ADCC and NK cells are 246 major producers of IFNγ (4, 35). NK92-CD64/16A cells exposed to SKOV-3 cells and 247 trastuzumab produced considerably higher levels of IFNγ than when exposed to SKOV-3 cells 248 alone (Fig. 2D) . Taken together, the above findings demonstrate that the CD64 component of the 249 recombinant receptor engages tumor-bound antibody, and that the CD16A component promotes 250 intracellular signaling leading to degranulation and cytokine production. 251 252
CD64 is distinguished from the other FcγR members by its unique third extracellular domain, 253 which contributes to its high affinity and stable binding to soluble monomeric IgG (26). We 254 compared the ability of NK92 cells expressing CD64/16A or the CD16A-176V higher affinity 255 variant to capture soluble therapeutic mAbs. The NK92 cell transductants examined expressed 256 similar levels of CD64/16A and CD16A (Figure 3A) . NK92 cell transductants were incubated 257 with trastuzumab for 2 hours, excess antibody was washed away, stained with a fluorophore-258 conjugated anti-human IgG antibody, and then evaluated by flow cytometry. As shown in Figure  259 3B, NK92-CD64/16A cells captured considerably higher levels of trastuzumab than did the 260 NK92-CD16A cells (8.1 fold increase ± 1.3, mean ± SD of 3 independent experiments). 261
Moreover, the NK92-CD64/16A cells efficiently captured the tumor-targeting mAbs 262
Erbitux/cetuximab and Rituxan/rituximab, as well as the fusion protein L-selectin/Fc (Fig. 3C) . 263 We then tested whether NK92-CD64/16A cells with a captured tumor-targeting mAb mediated 264 ADCC. For this assay, equal numbers of NK92-CD64/16A and NK92-CD16A cells were 265 incubated with the same concentration of soluble trastuzumab, washed, and exposed to SKOV-3 266 cells. Target cell killing by NK92-CD64/16A cells with captured trastuzumab was significantly 267
higher than NK92-CD64/16A cells alone, and was far superior to NK92-CD16A cells treated 268 with or without trastuzumab at all E:T ratios examined (Fig. 3D) . In contrast, SKOV-3 269 cytotoxicity by NK92-CD16A and NK92-CD64/16A cells was not significantly different if 270 trastuzumab was present and not washed out (Fig. 3E) , thus demonstrating equivalent 271 cytotoxicity by both transductants. Taken together, these findings show that NK92 cells 272 expressing CD64/16A can stably bind soluble anti-tumor mAbs and IgG fusion proteins, and that 273 these can serve as targeting elements to kill cancer cells. 274 275
Expression and function of CD64/16A in iPSC-derived NK cells. 276 We also examined the function of CD64/16A in engineered primary NK cells. Genetically 277 modifying peripheral blood NK cells by retroviral or lentiviral transduction at this point has been 278 challenging (36). Embryonic stem cells and iPSCs can be differentiated into cytolytic NK cells in 279 vitro (28-31, 37), and these cells are highly amendable to genetic engineering (14, 30, 38, 39) . 280
Undifferentiated iPSCs were transduced to express CD64/16A using a sleeping beauty 281 transposon plasmid for nonrandom gene insertion and stable expression. iPSCs were 282 differentiated into hematopoietic cells and then iNK cells by a two-step process (28, 29) . For this 283 study, we modified the hematopoietic differentiation method to streamline the procedure by 284 using a commercially available media and hematopoietic differentiation kit, as described in the 285
Materials and Methods. CD34 + CD43 + CD45 + cells were generated, further differentiated into 286 iNK cells, and these cells were expanded for analysis using recombinant IL-2 and aAPCs. 287 CD56 + CD3 − is a hallmark phenotype of human NK cells, and these cells composed the majority 288 of our differentiated cell population (Fig. 4) . We also assessed the expression of a number of 289 activating and inhibitory receptors on the iNK cells and compared this to peripheral blood NK 290 cells. Certain receptors were expressed by similar proportions of the two NK cell populations, 291 such as CD16A; however, the expanded iNK cells did lack expression of the inhibitory KIR 292 receptors KIR2DL2/3, KIR2DL1, and KIR3DL1 and also certain activating receptors (NKp46 293 and NKG2D) (Fig. 4) . Another difference compared to peripheral blood NK cells was that the 294 iNK cells were stained with an anti-CD64 mAb (Fig. 4) , demonstrating the expression of 295 CD64/16A. 296 297
To assess the function of CD64/16A in iNK cells, we compared iNK cells derived from iPSCs 298 transduced with either an pKT2 empty vector or pKT2-CD64/16A. The NK cell markers 299 mentioned above were expressed at similar levels and proportions by two iNK cell populations 300
(data not shown), including CD16A (Fig. 5A) , but only iNK-CD64/16A cells were stained by an 301 anti-CD64 mAb (Fig. 5A) . Both iNK tranductants demonstrated increased SKOV-3 cell killing 302 when in the presence of trastuzumab, yet iNK-CD64/16A cells mediated significantly higher 303 levels of ADCC than did the iNK-pKT2 control cells (Fig. 5B) . The anti-CD16 function 304 blocking mAb 3G8, but not the anti-CD64 mAb 10.1, effectively inhibited ADCC by the iNK-305 pKT2 cells (Fig. 5B) . Conversely, 10.1, but not 3G8, blocked ADCC by the iNK-CD64/16A 306 cells (Fig. 5B) . These findings show that the iNK cells were cytolytic effectors responsive to 307 CD16A and CD64/16A engagement of antibody-bound tumor cells. We also treated iNK-308 CD64/16A and iNK-pKT2 cells with soluble trastuzumab, washed away excess antibody, and 309 exposed them to SKOV-3 cells. Under these conditions, ADCC by the iNK-CD64/16A cells was 310 strikingly higher than the iNK-pKT2 cells (Fig. 5C) , further establishing that CD64/16A can 311 capture soluble anti-tumor mAbs that serve as a targeting element for tumor cell killing. 312 313
DISCUSSION
314
CD16A has an exclusive role in inducing ADCC by human NK cells (2-4). The affinity of 315 antibody binding and the expression levels of this IgG Fc receptor modulate NK cell effector 316 functions and affect the efficacy of tumor-targeting therapeutic mAbs (4, 11, 19, 20) . To enhance 317
anti-tumor antibody binding by NK cells, we expressed a novel recombinant FcγR consisting of 318 the extracellular region of the high affinity FcγR CD64 and the transmembrane and intracellular 319 regions of CD16A. NK cells expressing CD64/16A facilitated cell conjugation with antibody-320 bound tumor cells, cytotoxicity, and IFNγ production, demonstrating function by both 321 components of the recombinant FcγR. CD64/16A lacks the ADAM17 cleavage region found in 322 CD16A and it did not undergo the same level of downregulation in expression during ADCC. 323
Consistent with the ability of CD64 to stably bind soluble monomeric IgG, NK cells expressing 324 CD64/16A could capture soluble anti-tumor therapeutic mAbs and kill target cells. 325 326 CD64/16A was shown to be functional in two NK cell platforms, the NK92 cell line and primary 327 NK cells derived from iPSCs. NK92 cells lack inhibitory KIR receptors and show high levels of 328 natural cytotoxicity compared to other NK cell lines derived from patients (40). NK92 cells have 329 been broadly used to express modified genes to direct their cytolytic effector function, have been 330 evaluated in preclinical studies, and are undergoing clinical testing in cancer patients (40, 41) . 331
iPSCs are also very amendable to genetic engineering and can be differentiated into NK cells 332
expressing various receptors to direct their effector functions (14, 30, 38, 39) . The iNK cells 333 generated in this study lacked several inhibitory and activating receptors indicating an immature 334 state. In previous studies we have generated iNK cells with a phenotype indicative of a more 335 mature cellular stage (29-31), which may be the result of different culture conditions. A key 336 change for the current study was the use of a hematopoietic differentiation kit to simplify the 337 differentiation procedure. The phenotype of the iNK cells will be important for the desired 338 effector functions. It could be beneficial if therapeutic iNK cells administered to cancer patients 339 lacked inhibitory receptors and certain activating receptors in order to direct and optimize their 340 tumor cell killing by engineered receptors. The iNK cells did express endogenous CD16A and 341 mediated ADCC, thus they were cytotoxic effector cells. We found that for pKT2 vector control 342 iNK cells, ADCC was blocked by an anti-CD16 mAb. Interestingly, ADCC by the iNK-343 CD64/16A cells was blocked by an anti-CD64 mAb but not by an anti-CD16 mAb. Why 344 endogenous CD16A in the iNK-CD64/16A cells did not have a role in the in vitro ADCC assay 345 is unclear at this time. This may be due to a competitive advantage by CD64/16A in binding 346 antibody and/or in utilizing the same pool of downstream signaling factors. 347 348
An individual NK cell can kill multiple tumor cells in different manners. This includes by a 349 process of sequential contacts and degranulations, referred to as serial killing (42, 43) expressing CD64/16A with an antibody would also reduce the dosage of therapeutic antibodies 366 administered to patients. We showed that fusion proteins containing a human IgG Fc region, 367 such as L-selectin/Fc, can also be captured by CD64/16A and this may provide further options 368 for directing the tissue and tumor antigen targeting of engineered NK cells. Advantages of the 369 NK92 and iNK cell platforms for adoptive cell therapies is that they can be readily gene 370 modified on a clonal level and expanded into clinical-scalable cell numbers to produce 371 engineered NK cells with improved effector activities as an off-the-shelf therapeutic for cancer 372 immunotherapy (37, 38, 40, 41, 47) . 373 ADAM17 at a membrane proximal location, as indicated, which is not present in CD64 and 580 CD64/16A. (B) NK92 parental cells, NK92-CD16A cells, and NK92-CD64/16A cells were 581 stained with an anti-CD16, anti-CD64, or an isotype-matched negative control mAb and 582 examined by flow cytometry. (C) NK92-CD16A and NK92-CD64/16A cells were incubated 583 with SKOV-3 cells with or without trastuzumab (5μg/ml) at 37 o C (E:T = 1:1) for 2 hours. The 584
Figure legends
NK92-CD16A and NK92-CD64/16A cells were then stained with an anti-CD16 mAb or an anti-585 CD64 mAb, respectively, and examined by flow cytometry. Nonspecific antibody labeling was 586 determined using the appropriate isotype-negative control mAb. Data is representative of at least 587 3 independent experiments. 588 589 Fig. 2 . CD64/16A promotes target cell conjugation, ADCC, and IFNγ production. (A) 590 NK92-CD64/16A cells expressing eGFP and SKOV-3 cells labeled CellTrace Violet were mixed 591
at an E:T ratio of 1:2 with or without trastuzumab (5μg/ml), incubated at 37 °C for 60 minutes, 
